Director/PDMR Shareholding

Summary by AI BETAClose X

Nigel Reynolds, a Director of BioPharma Credit PLC, has purchased shares in the company on July 31, 2026, on the London Stock Exchange. The transactions involved acquiring a total of 27,124.8 ordinary shares at prices ranging from $0.968 to $0.970. This purchase by a director is an initial notification and indicates a personal investment in the company's stock.

Disclaimer*

BioPharma Credit PLC
03 August 2026
 

BIOPHARMA CREDIT PLC

 

Notification of Transactions by

Persons Discharging Managerial Responsibilities and

Persons Closely Associated with them

 

1.

Details of person discharging managerial responsibilities/person closely associated with them

a)

Name

Nigel Reynolds

2.

Reason for the notification

a)

Position / status

Director of BioPharma Credit PLC

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

BioPharma Credit PLC

b)

LEI

213800AV55PYXAS7SY24

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares of $0.01 each

 

 

GB00BDGKMY29

b)

Nature of the transaction

Purchase of Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$0.970

13,147.53

$0.969

9866.00

$0.968

4111.27

d)

Aggregated information

- Aggregated volume

 

- Price

 

 

N/A

e)

Date of the transaction

31.07.2026

f)

Place of the transaction

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings